Xenalten - instructions for use, analogs, reviews and release forms (capsules or tablets 120 mg for weight loss) of the drug to reduce excess weight in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Xenalten. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Xenalten in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Xenalten in the presence of existing structural analogs. Use to reduce excess weight in adults, children, as well as during pregnancy and lactation. Composition of the drug for weight loss.

Xenalten - a specific inhibitor of gastrointestinal lipases. Forms a covalent bond with the active serine region of the gastric and pancreatic lipases in the lumen of the stomach and small intestine. The inactivated enzyme loses the ability to break down food fats that come in the form of triglycerides (TG). Undivided TG is not absorbed, and the consequent decrease in the intake of calories into the body leads to a decrease in body weight. Increases the concentration of fat in the stool after 24-48 hours after ingestion. Provides effective control of body weight, reduction of fat depot.

For the manifestation of activity, no systemic absorption of Orlistat (the active substance of the Xenalten preparation) is required, at a recommended therapeutic dose (120 mg 3 times a day), it inhibits approximately 30% absorption of incoming fats.

Composition

Orlistat + auxiliary substances.

Pharmacokinetics

Absorption is low; 8 hours after ingestion, unchanged orlistat in plasma is not detected. More than 99% associated with plasma proteins, mainly with lipoproteins and albumin. Orlistat minimally penetrates into the red blood cells.Metabolized mainly in the wall of the gastrointestinal tract (GIT) with the formation of pharmacologically inactive metabolites Ml (hydrolyzed four-membered lactone ring) and M3 (M1 with the cleaved N-formylleucine residue). After a single oral intake of 360 mg of 14C-orlistat by patients with normal body weight and obese, excretion of unsweetened orlistat through the intestine was the main route of excretion. Orlistat and its metabolites M1 and M3 also undergo excretion with bile. About 97% of the radiolabeled substance introduced was excreted with feces, incl. 83% - unchanged. The time of complete elimination with feces and urine is 3-5 days. The excretion of orlistat was similar in patients with normal body weight and with obesity.

Indications

Treatment of obesity, incl. reduction and maintenance of body weight, in combination with a hypocaloric diet.

Orlistat is also indicated to reduce the risk of repeated weight gain after its initial decline.

Orlistat is indicated in obese patients with a body mass index (BMI) of more than 30 kg / m2 or more than 28 kg / m2 in the presence of other risk factors (diabetes mellitus, hypertension, dyslipidemia).

Forms of release

Capsules 120 mg (sometimes mistakenly called pills).

Instructions for use and reception scheme

Inside, 120 mg (1 capsule) 3 times a day during each meal or not later than 1 hour after a meal (if the food does not contain fat, then you can skip the reception).

Side effect

• oily discharge from the rectum;
• the emission of gases with a certain amount of detachable;
• imperative urges for defecation;
• steatorrhea;
• more bowel movements;
• loose stools;
• flatulence;
• pain or discomfort in the abdomen;
• a soft chair;
• pain or discomfort in the rectum;
• fecal incontinence;
• bloating;
• damage to teeth;
• defeat of gums;
• upper respiratory tract infection;
• infections of the lower respiratory tract;
• itching;
• hives;
• rash;
• angioedema;
• bronchospasm;
• anaphylaxis;
• headache;
• increased activity of transaminases and alkaline phosphatase;
• hepatitis;
• urinary tract infections;
• dysmenorrhea;
• anxiety;
• weakness.

Contraindications

• hypersensitivity to orlistat or other components of the drug;
• malabsorption syndrome;
• cholestasis;
• simultaneous reception with cyclosporine;
• pregnancy;
• lactation;
• age to 18 years.

Application in pregnancy and lactation

Xenalten is contraindicated to be used during pregnancy due to the lack of reliable clinical data confirming the safety of its use.

It is not established whether orlistat penetrates into breast milk, and therefore the use of Xenalten during breast-feeding is not recommended.

Use in children

Xenalten is not intended for use in children's practice (in children under 18 years of age).

special instructions

During the treatment it is necessary to observe a balanced, low-calorie diet containing no more than 30% of calories in the form of fats and enriched with fruits and vegetables (optional addition of multivitamins to compensate for reduced absorption of fat-soluble vitamins).

Before the appointment of orlistat should be deleted organic cause of obesity, for example hypothyroidism.

The likelihood of side effects from the gastrointestinal tract increases with a high content of fat in the diet (more than 30% of daily calories). Daily intake of fats, carbohydrates and proteins should be distributed among the three main meals. Since orlistat reduces the absorption of some fat-soluble vitamins, patients must take multivitamin preparations containing fat-soluble Vitamins to ensure their adequate intake.In addition, the content of vitamin D and beta-carotene in obese patients may be lower than in people who are not obese. Multivitamins should be taken 2 hours before or 2 hours after taking orlistat, for example, before going to bed. The intake of orlistat at doses exceeding 120 mg 3 times a day does not provide an additional effect.

If simultaneous intake of orlistat with cyclosporine is not possible, continuous monitoring of cyclosporin content in plasma is necessary.

In patients who did not receive prophylactic vitamin supplements, with two or more consecutive visits to the doctor during the first and second years of treatment with orlistat, a decrease in the level of vitamins in plasma was recorded.

In some patients, the content of oxalate in urine may increase with orlistat.

As with other drugs to reduce body weight, in some groups of patients (for example, with anorexia nervosa or bulimia), there is a possibility of abuse of orlistat.

Since the absorption of vitamin K can be reduced when taking orlistat, patients who receive orlistat with long-term continuous use of Warfarin should monitor the parameters of blood coagulation.

Orlistat's induction of weight loss can be combined with an improvement in the metabolic control of diabetes mellitus, which will require a reduction in the doses of oral hypoglycemic agents (sulfonylureas, metformin, etc.) or insulin.

If, after 12 weeks of therapy with Xenalten, a decrease in body weight is less than 5% of the original, a doctor's consultation is needed to decide whether to continue treatment with orlistat.

Treatment should not last more than 2 years.

Impact on the ability to drive vehicles and manage mechanisms

Does not affect the ability to drive vehicles and service moving machinery.

Drug Interactions

Xenalten does not affect the pharmacokinetics of ethanol (alcohol), Digoxin (prescribed in a single dose) and phenytoin (prescribed in a single dose of 300 mg), on the bioavailability of Nifedipine (sustained-release tablets). Ethanol does not affect pharmacodynamics (excretion of fats with feces) and systemic exposure of orlistat.

With the simultaneous use of orlistat and cyclosporine, the plasma level in the plasma decreases (orlistat and cyclosporine should not be takensimultaneously; to reduce the likelihood of drug interaction, cyclosporine should be taken 2 hours before or 2 hours after taking orlistat).

With the simultaneous use of warfarin or other indirect anticoagulants with orlistat, the level of prothrombin can decrease and the value of the indicator of the international normalized ratio (MHO) may change, therefore MHO control is necessary.

Orlistat reduces the absorption of beta-carotene contained in food additives by 30% and inhibits the absorption of vitamin E (in the form of tocopherol acetate) by approximately 60%.

Increases the bioavailability and hypolipidemic effect of pravastatin, increasing its concentration in plasma by 30%.

At simultaneous reception with Xenalten, absorption of vitamins A, D, E and K is reduced. If multivitamins are recommended, they should be taken no less than 2 hours after taking Xenalten or before bedtime.

Decreased body weight can improve metabolism in diabetic patients, and as a result, it is necessary to reduce the dose of oral hypoglycemic drugs.

It is not recommended simultaneous use with acarbose due to the lack of data on pharmacokinetic interactions.

With simultaneous use with orlistatom a decrease in the level of Amiodarone in the plasma after a single dose. Simultaneous use of orlistat and amiodarone is possible only on the advice of a doctor.

Xenalten can indirectly reduce the bioavailability of oral contraceptives, which can lead to the development of unwanted pregnancies. It is recommended to use additional types of contraception in case of acute diarrhea.

Clinically significant interactions with digoxin, amitriptyline, phenytoin, fluoxetine, sibutramine, atorvastatin, pravastatin, nifedipine, losartan, glibenclamide, furosemide, captopril, atenolol, and ethanol were not noted.

Analogs of the Xenalten drug

Structural analogs for the active substance:

• Allie;
• Xenical;
• Listat;
• Listata Mini;
• Orlimax;
• Orlimax Light;
• Orlistat;
• Orlistat the Canon;
• Orsotene;
• Orsoten Slim.

Similar medicines:

Other medicines: